Bookmark

Add to MyYahoo RSS

Celgene News

News on Celgene (Ticker: CELG) continually updated from thousands of sources around the net.

5 hrs ago | Investor's Business Daily

Bristol-Myers Squibb and Celgene Enter Clinical Collaboration...

Phase I study to evaluate OPDIVO , Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, with Celgene's ABRAXANE A for multiple cancers NEW YORK & SUMMIT, N.J.-- -- Bristol-Myers Squibb Company and Celgene Corporation announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

INCROYABLE - Relais France 4x400m Femme - Championnats d'Europe 2014 - INCREDIBLE F...

Should the U.S. Capitol Have a POW/MIA Memorial?

This Cover of 'Girls Just Wanna Have Fun' is Hauntingly Beautiful

George W. Bush Just Took The ALS Ice Bucket Challenge And It's Pretty Hilarious

5 hrs ago | Wall Street Journal

Bristol-Myers, Celgene to Collaborate on Cancer-Treatment Study

Bristol-Myers Squibb Co. and Celgene Corp. have agreed to collaborate on a clinical study for a potential cancer treatment that will combine immunotherapy and chemotherapy, the companies said Wednesday.

Comment?

Related Topix: Medicine, Cancer, Biotech, Bristol Myers Squibb, Healthcare Industry

Tue Aug 19, 2014

BioSpace

Celgene Corporation Release: Clinical Study In The Reports Patients...

Celgene Corporation today announced that results of a study evaluating the combination of REVLIMIDA with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology.

Comment?

Related Topix: Biotech, Healthcare Industry, Cyclophosphamide (generic), Cytoxan

Mon Aug 18, 2014

Investor's Business Daily

New High Analysis: Celgene, Regeneron Pad Gains

A solid up day for the market Monday, albeit in lower volume, resulted in no shortage of new highs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Benzinga

Pharmacyclics Appoints Chief Commercial Officer

Pharmacyclics, Inc. today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer.

Comment?

Related Topix: Startups, Pharmacyclics, Oncology, Medicine, Biotech, Healthcare Industry, Marketing

AmericanBankingNews.com

Celgene Hits New 1-Year High at $92.07

Celgene reached a new 52-week high during mid-day trading on Monday , Analyst Ratings Network.com reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene

Investor's Business Daily

Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

Its narcolepsy treatment, Xyrem, has rocketed to success and contributed to 65% of the drugmaker's 2013 revenue .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene, Financial Markets

Seeking Alpha

Taking Profits From Netflix And Putting Them To Work In Celgene

At this point in the stock market I want to swap out of expensively valued stocks into at least fairly valued ones such as the swap I'm mentioning today.

Comment?

Related Topix: Netflix, Startups, Biotech, Medicine, Healthcare Industry, Celgene, Financial Markets

Thu Aug 14, 2014

Minyanville

Biotech Leads the Way

You will receive a download link right in your email inbox for each of the free reports that you choose.

Comment?

Related Topix: Startups, Pharmacyclics, Biotech, Medicine, Celgene, Healthcare Industry, Gilead Sciences

Tue Aug 12, 2014

Hispanic Business

bluebird bio Reports Fiscal Second Quarter 2014 Financial Results

"In June, we presented some very encouraging clinical data on our LentiGlobin product candidate for beta-thalassemia at the EHA conference in .

Comment?

Related Topix: Genetics, Medicine, Biotech, Healthcare Industry

Mon Aug 11, 2014

BioSpace

Celgene Corporation And Celgene Cellular Therapeutics Sign License...

Celgene Corporation And Celgene Cellular Therapeutics Sign License Agreement To Develop And Commercialize Placental Stem Cell Population, PSC-100 For Multiple Therapeutic Applications /PRNewswire/ -- Human Longevity, Inc. , a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Stem Cell Research, Science / Technology, Biology

Fri Aug 08, 2014

Seeking Alpha

The Case That Regeneron May Be Significantly Undervalued

The combination of high R&D spending and elevated pre-launch expenses for its late-stage cholesterol reducer alirocumab means that P/E is the wrong metric investors should look at.

Comment?

Related Topix: Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Pharmacology, Manufacturing, Bayer HealthCare, Chemicals

Thu Aug 07, 2014

Seeking Alpha

2 Huge Immunology Opportunities For Celgene

Oral Otezla won't entirely displace injected biologics, but safety and convenience should easily push it over the $1 billion mark.

Comment?

Related Topix: Biotech, Celgene, Healthcare Industry, Psoriatic Arthritis, Health, Healthcare Law, Law

Wed Aug 06, 2014

AmericanBankingNews.com

Celgene Given New $100.00 Price Target at RBC Capital

The firm currently has an "outperform" rating on the stock. RBC Capital's price target points to a potential upside of 16.10% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene

Barron's

Celgene: Five Reasons to Be Bullish

If the big-five biotechs were the Rat Pack , Celgene would be Joey Bishop , to Amgen's Frank Sinatra, Biogen's Dean Martin and Gilead Sciences Sammy Davis Jr. Peter Lawford.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, The Rat Pack, Vocal, Amgen, Gilead Sciences, Regeneron Pharmaceuticals

Tue Aug 05, 2014

AmericanBankingNews.com

Insider Selling: Perry A. Karsen Sells 39,104 Shares of Celgene Stock

Celgene Insider Perry A. Karsen sold 39,104 shares of the stock on the open market in a transaction dated Monday, August 4th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene

Seeking Alpha

Aspire Data A Big Plus For Amgen And Celgene

Strong interim data Yesterday, Amgen released data from a planned interim analysis of the Aspire study that could lead to a significant sales boost.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Celgene, Startups, Onyx Pharmaceuticals, Johnson and Johnson

Thu Jul 31, 2014

Business Journal

Big biotech signals strategic move into Seattle; Is a buyout next?

Bob Hugin, chief executive officer of Celgene Corp., reported second-quarter results of $748 million in net income.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene, VentiRx Pharmaceuticals, Oncology, Summit, NJ

Seeking Alpha

Celgene: Constantly Adding Signature Drugs To Its Healthy Portfolio

Future revenue growth: introducing Otezla in other markets and researching on four other indications that can be treated by Otezla in order to earn higher revenue from this drug.

Comment?

Related Topix: Biotech, Healthcare Industry, Celgene

Freshnews

The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Comment?

Related Topix: Biotech, Medicine, Science / Technology, Gilead Sciences, Healthcare Industry, Celgene, Financial Markets, Cancer, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••